Page 90 - Read Online
P. 90
Page 6 of 9 Cross et al. J Cancer Metastasis Treat 2021;7:55 https://dx.doi.org/10.20517/2394-4722.2021.99
Figure 2. Progression-free survival of immediate vs. deferred cytoreductive nephrectomy in the SURTIME trial.
Figure 3. Kaplan-Meier estimates of overall survival comparing nephrectomy plus sunitinib vs. sunitinib alone in the CARMENA trial.
an additional 18% never received systemic therapy. In the sunitinib-only arm, 5% of patients didn’t receive
the planned systemic therapy, and an additional 17% subsequently underwent nephrectomy. A per-protocol
analysis including only those patients who were treated as assigned showed a median OS of 20.5 months for
the sunitinib-only group vs. 18.3 months in the cytoreductive nephrectomy group. Based on this analysis,
making definitive conclusions from the study is more difficult.
